Capmatinib hydrochloride

Capmatinib Hydrochloride is the hydrochloride salt form of capmatinib, an orally bioavailable inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with potential antineoplastic activity. Capmatinib selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis. It is grouped under the following drug class(es): Kinase inhibitors and Tyrosine Kinase Inhibitors. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Tabrecta and Capmatinib dihydrochloride hydrate. Its PubChem CID is 122201352.